STOCK TITAN

Kane Biotech Inc. - KNBIF STOCK NEWS

Welcome to our dedicated news page for Kane Biotech (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kane Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kane Biotech's position in the market.

News
Rhea-AI Summary
Kane Biotech Inc. announces an investor webinar to discuss the sale of STEM Animal Health, expected to bring in over $13 million CND. The sale is a strategic move to position Kane as a market leader in wound care and dermatological markets, enhancing the company's focus and financial stability for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Kane Biotech completes the sale of STEM Animal Health to Dechra Veterinary Products for US $8 million, positioning Kane as a market leader in wound care and dermatological markets. The sale is expected to net Kane approximately CND $13 million, allowing for key milestones in commercial launches, global growth, and clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kane Biotech Inc. announces the sale of its interest in STEM Animal Health Inc. to a multi-national pharmaceutical company for US $8,000,000, with additional consideration totaling over CND $11,500,000. The company will use the proceeds to repay its loan and for general working capital purposes, strengthening its balance sheet. The transaction includes a sales-based milestone payment and agreements for product development and transitional manufacturing with STEM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kane Biotech Inc. announces its financial results for Q4 and full year 2023, revealing a non-binding offer for its interest in STEM Animal Health. The company received deposits totaling US $1.525 million towards the sale. Q4 saw positive revenue growth with an increase in license and royalty income by 66%, product revenue by 9%, and total revenue by 11%. However, operating expenses surged by 96%, leading to a loss of ($1,611,894) for the quarter. Full year 2023 showed a decrease in license and royalty income by 22% but an increase in product revenue by 25%. Despite a 6% rise in total revenue, the company reported a higher loss of ($5,270,053) for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. extends the exclusivity period for its interest in STEM Animal Health until March 31, 2024. The company has received additional deposits totaling US $900,000 towards the sale price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kane Biotech Inc. to announce Q4 and full year 2023 financial results on March 26, 2024. Conference call to discuss results and business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech Inc. receives the BAM Company of the Year award for its significant achievements in 2023, including FDA clearance, distribution agreements, licensing agreements, and revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kane Biotech Inc. appoints Dr. Robert Huizinga as a director and Executive Chair, focusing on strategic initiatives and partnerships to enhance wound and skin care solutions. Dr. Huizinga's background in Nephrology and successful FDA approval history brings valuable expertise to Kane Biotech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kane Biotech Inc. announces the introduction of its revyve™ Antimicrobial Wound Gel Spray at the Boswick Burn and Wound Care Symposium. The spray gel, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, has been patented and is designed to simplify application to wounds, reduce infection risk, and minimize pain for patients. The product is pending FDA clearance and is expected to have a significant impact on treating sensitive wounds, particularly burns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kane Biotech Inc. announces the presentation of its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The gel, featuring thermo-reversible properties, is designed for sensitive wounds such as burns and offers prolonged antimicrobial activity in a moist environment. Dr. Gregory Schultz, Chief Scientific Officer, expresses excitement for the presentation and anticipates a positive reception within the wound care community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Kane Biotech Inc.

OTC:KNBIF

KNBIF Rankings

KNBIF Stock Data

12.04M
82.80M
36.45%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Winnipeg